Therapeutic potential of monoclonal antibodies in myocardial reperfusion injury

American Journal of Cardiovascular Drugs

Volumn 2, Issue 6, 2002, Pages 367-376

  Nigam, Anil ^a   Kopecky, Stephen L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CD11B ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C5A; CYTOKINE; DREG 200; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERLIZUMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HU DREG 200; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; L SELECTIN; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CLB54; MONOCLONAL ANTIBODY R15 7; PADGEM PROTEIN; PADGEM PROTEIN LIGAND 1 DERIVATIVE; PEXELUZIMAB; PLACEBO; ROVELIZUMAB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CELL INTERACTION; DRUG TARGETING; ENDOTHELIUM CELL; GENE THERAPY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE INJURY; HUMAN; LEUKOCYTE; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL REPERFUSION INJURY;

EID: 0036958769     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202060-00002     Document Type: Review

References (83)

1. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89: 61-7
2. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
3. Duilio C, Ambrosio G, Kuppusamy P, et al. Neutrophils are primary source of O2 radicals during reperfusion injury after prolonged myocardial ischemia. Am J Physiol 2001; 280: H2649-57
4. Heymans S, Lutton A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5 (10): 1135-42
5. Hammerman H, Kloner RA, Hale S, et al. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation 1983; 68: 446-52
6. Frangogiannis NG, Youker KA, Rossen RD, et al. Cytokines and the microcirculation in ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 2567-76
7. Crawford MH, Grover FL, Kolb WP, et al. Complement and neutrophil activation in the pathogenesis of myocardial injury. Circulation 1988; 78: 1449-58
8. Birdsall HH, Green D, Trial J, et al. Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 1997; 95: 684-92
9. von Andrian UH, Chambers JD, McEvoy LM, et al. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte β2 integrins in vivo. Proc Natl Acad Sci U S A 1991; 88: 7538-42
10. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell weibel-palade bodies. J Clin Invest 1996; 97: 493-500
11. Moore KL, Eaton SF, Lyons DE, et al. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. J Biol Chem 1994; 269: 23318-27
12. Moore KL, Patel KD, Bruehl RE, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol 1995; 128: 661-71
13. Chamoun F, Burne M, O'Donnell M, et al. Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury. Front Biosci 2000; 5: 103-9
14. Fraticelli A, Serrano Jr CV, Bochner BS, et al. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta 1996; 1310: 251-9
15. Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecule mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 1993; 120: 545-56
16. Frangogiannis NG, Youker KA, Rossen RD, et al. Cytokines and the microcirculation in ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 2567-76
17. Bowden RA, Ding Z-M, Donnachie EM, et al. Role of α4 integrin and VCAM-1 in CD18-independent neutrophil migration across mouse cardiac endothelium. Circ Res 2002; 90: 562-9
18. Jordan JE, Zhao ZQ, Vinten-Johnansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43 (4): 860-78
19. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alpha 2 beta 3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-93
20. Kupatt C, Hanusch P, Habazettl H, et al. Abciximab reduces postischemic stunning caused by platelet-PMN interaction in isolated hearts [abstract]. Circulation 1999; 100 Suppl. 1: I-545
21. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-α-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158: 5435-41
22. Kupatt C, Habazettl H, Becker BF, et al. Endothelial activation: a strategic event during postischemic myocardial inflammation. Z Kardiol 2000; 89 (9 Suppl.): 96-100
23. Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 1997; 401: 30-4
24. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-α initiating the cytokine cascade in myocardial infarction/reperfusion. Circulation 1998; 98: 699-710
25. Youker KA, Smith CW, Anderson DC, et al. Neutrophil adherence to isolated cardiac myocytes: induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest 1992; 89: 602-9
26. Kukielka GL, Hawkins HK, Michael LH, et al. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused myocardium. J Clin Invest 1993; 92: 1504-16
27. Entman ML, Youker KA, Shappell SB, et al. Neutrophil adherence to isolated canine myocytes: evidence for a CD18-dependent mechanism. J Clin Invest 1990; 85: 1497-506
28. Entman ML, Youker KA, Shoji T, et al. Neutrophil induced oxidative injury of cardiac myocytes: a compartmented system requiring CD11b/CD-18-ICAM-1 adherence. J Clin Invest 1992; 90: 1335-45
29. Vakeva AP, Azin A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259-67
30. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immumol 1996; 33: 1389-401
31. Fitch JCK, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100: 2499-506
32. Anon. Alexion begins phase III pivotal PRIMO-CABG trial [online]. Available from URL: http://www/AlexionPharm.com/news/ [Accessed 2002 Apr 22]
33. Anon. Alexion completes enrollment in first two acute myocardial infarction phase II trials with pexelizumab [online]. Available from URL: http://www.AlexionPharm.com/news/ [Accessed 2002 Apr 22]
34. Bahit MC, Granger CB. Current trials in acute myocardial infarction. Cardiology Spec Ed 2001; 7 (2 of 2): 49-55
35. Lefer DJ. Pharmacology of selectin inhibitors in ischemia/reperfusion states. Annu Rev Pharmacol Toxicol 2000; 40: 283-94
36. Weyrich AS, Ma XL, Lefer DJ, et al. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993; 91: 2620-9
37. Chen LY, Nichols WW, Hendricks JB, et al. Monoclonal antibody to P-selectin (PB1.3) protects against myocardial reperfusion injury in the dog. Cardiovasc Res 1994; 28: 1414-22
38. Lefer DJ, Flynn DM, Buda AJ. Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am J Physiol 1996; 270: H88-98
39. Yamada K, Tojo SJ, Hayashi M, et al. The role of P-selectin, sialyl Lewis X and sulfatide in myocardial ischemia and reperfusion injury. Eur J Pharmacol 1998; 346: 217-25
40. Jones SP, Girod WG, Granger DN, et al. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am J Physiol 1999; 46: H763-9
41. Hayward R, Campbell B, Shin YK, et al. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41: 65-76
42. Lefer Am, Campbell B, Scalia R, et al. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 1998; 98: 1322-8
43. Ma XL, Weyrich AS, Lefer DJ, et al. Myocardial ischemia/reperfusion: monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation 1993; 88: 649-58
44. Buerke M, Weyrich AS, Murohara T, et al. Humanized monoclonal antibody DREG-200 directed against L-selectin protects in feline myocardial reperfusion injury. J Pharmacol Exp Ther 1994; 271: 134-42
45. Mihelcic D, Schleiffenbaum B, Tedder TF, et al. Inhibition of leukocyte L-selectin function with a monoclonal antibody attenuates reperfusion injury to the rabbit ear. Blood 1994; 84: 2322-8
46. Yan ZQ, Bolognesi MP, Steeber DA, et al. Blockade of L-selectin attenuates reperfusion injury in a rat model. J Reconstr Microsurg 2000; 16 (3): 227-33
47. Weyrich AS, Buerke M, Albertine KH, et al. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukoc Biol 1995; 57 (1): 45-55
48. Kurose I, Anderson DC, Miyasaka M, et al. Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res 1994; 74: 336-43
49. Winquist RJ, Frei PF, Letts G, et al. Monoclonal antibody to intercellular adhesion molecule-1, but not to endothelial-leukocyte adhesion molecule-1, protects against myocardial ischemia/reperfusion damage in anesthetized monkeys [abstract]. Circulation 1992; 86: I-79
50. Shyu K-G, Chang H, Lin CC, et al. Circulating intercellular adhesion molecule-1 and E-selectin in patients with acute coronary syndrome. Chest 1996; 19: 1627-30
51. Simpson PJ, Todd III RF, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988; 81: 624-9
52. Simpson PJ, Todd RF III, Mickelson JK, et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 1990; 81 (1): 226-37
53. Dreyer WJ, Michael LH, West MS, et al. Neutrophil accumulation in ischemic canine myocardium: insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation 1991; 84: 400-11
54. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991; 88: 1237-43
55. Lefer DJ, Shandelya SM, Serrano Jr CV, et al. Molecular and cellular cardiology: cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation 1993; 88: 1779-87
56. Aversano T, Zhou W, Nedelman M, et al. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J Am Coll Cardiol 1995; 25: 781-8
57. Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty: the FESTIVAL Study. Am J Cardiol 2001; 88: 482-7
58. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Circulation 2001; 104: 2778-83
59. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-701
60. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI-14 Trial. Circulation 2000; 101: 239-43
61. Ma XL, Lefer DJ, Lefer AM, et al. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule in myocardial ischemia and reperfusion. Circulation 1992; 86: 937-46
62. Faxon DP, Gibbons RJ, Chronos NAF, et al. The effect of a CD11/CD18 inhibitor (Hu23F2G) on infarct size following direct angioplasty: the HALT MI Study [abstract]. Circulation 1999; 100 (18): 1-791
63. Liles WC, Dale DC, Price TH, et al. Inhibition of in vivo neutrophil transmigration by a novel humanized anti-CD11/CD18 monoclonal antibody. Cytokines Cell Mol Ther 2000; 6: 121-6
64. Bowen JD, Petersdorf SH, Richards TL, et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998; 64 (3): 339-46
65. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35
66. Dove A. CD18 trials disappoint again. Nat Biotechnol 2000; 18 (8): 817-8
67. Kokura S, Wolf RE, Yoshikawa T, et al. Molecular mechanisms of neutrophil-endothelial cell adhesion induced by redox imbalance. Circ Res 1999; 84: 516-24
68. Mori N, Horie H, Gerritsen ME, et al. Ischemia-reperfusion induced microvascular responses in LDL-receptor -/- mice. Am J Physiol 1999; 276: H1647-54
69. Lefer DJ, Flynn DM, Anderson DC, et al. Combined inhibition of P-selectin and ICAM-1 reduces myocardial injury following ischemia and reperfusion. Am J Physiol 1996; 271: H2421-9
70. Tamiya Y, Yamamoto N, Uede T. Protective effect of monoclonal antibodies against LFA-1 and ICAM-1 on myocardial reperfusion injury following global ischemia in rat hearts. Immunopharmacology 1995; 29: 53-63
71. Neumann F-J, Zohlnhöfer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6
72. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999; 138 (1 Suppl. Pt 2): S1-5
73. Plescia J, Conte MS, VanMeter G, et al. Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem 1998; 273: 20372-7
74. Furman MI, Krueger LA, Frelinger AL, et al. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation [abstract]. J Am Coll Cardiol 1999; 100: I-857
75. Morel JCM, Park CC, Woods JM, et al. A novel role for interleukin-18 in adhesion molecule induction through NF-κB and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001; 276: 37069-75
76. Tsuruma T, Yagihashi A, Tarumi K, et al. Anti-rat IL-8 (CINC) monoclonal antibody administration reduces ischemia-reperfusion injury in small intestine. Transplant Proc 1998; 30: 2644-5
77. Kokura S, Wolf RE, Yoshikawa T, et al. T-lymphocyte-derived tumor necrosis factor exacerbates anoxia-reoxygenation-induced neutrophil-endothelial cell adhesion. Circ Res 2000; 86: 205-13
78. Kim CD, Kim YK, Lee SH, et al. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor. J Pharmacol Exp Ther 2000; 294 (3): 864-9
79. Krishnadasan B, Naidu B, Rosengart M, et al. Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus. J Thorac Cardiovasc Surg 2002; 123: 756-67
80. Chatterjee PK, Brown PA, Cuzzocrea S, et al. Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat. Kidney Int 2001; 59: 2073-83
81. Elliott GT, Sowell CG, Walker EB, et al. The novel glycolipid RC-552 attenuates myocardial stunning and reduces infarct size in dogs. J Mol Cell Cardiol 2000; 32: 1327-39
82. Matsubara A, Tomida K, Matsuda Y, et al. Protective effects of selectin ligands/inhibitor (SKK-60060) against retinal ischemia-reperfusion injury. Exp Eye Res 2000; 71: 283-93
83. Zoldhelyi P, Beck PJ, Bjercke RJ, et al. Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor. Am J Physiol 2000; 279: H3065-75